Wall Street brokerages expect TearLab Corporation (NASDAQ:TEAR) to post sales of $6.90 million for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for TearLab Corporation’s earnings, with estimates ranging from $6.72 million to $7.07 million. TearLab Corporation reported sales of $7.22 million in the same quarter last year, which indicates a negative year over year growth rate of 4.4%. The company is expected to issue its next earnings report on Monday, November 6th.

According to Zacks, analysts expect that TearLab Corporation will report full year sales of $6.90 million for the current year, with estimates ranging from $27.60 million to $28.01 million. For the next fiscal year, analysts forecast that the firm will report sales of $29.81 million per share. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover TearLab Corporation.

TearLab Corporation (NASDAQ:TEAR) last announced its earnings results on Monday, August 14th. The medical research company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. The firm had revenue of $7 million during the quarter, compared to analysts’ expectations of $6.86 million. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.08) EPS.

Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of TearLab Corporation from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a research note on Friday. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of TearLab Corporation in a research note on Tuesday, August 15th. Finally, Rodman & Renshaw dropped their price target on shares of TearLab Corporation from $12.00 to $4.00 and set a “buy” rating on the stock in a research note on Tuesday, May 16th. Five equities research analysts have rated the stock with a buy rating, TearLab Corporation presently has an average rating of “Buy” and an average price target of $4.95.

COPYRIGHT VIOLATION NOTICE: This story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/08/21/zacks-analysts-anticipate-tearlab-corporation-tear-will-announce-quarterly-sales-of-6-90-million.html.

TearLab Corporation (TEAR) opened at 1.60 on Monday. The firm has a 50 day moving average of $2.10 and a 200 day moving average of $2.81. The firm’s market cap is $9.19 million. TearLab Corporation has a 1-year low of $1.53 and a 1-year high of $8.20.

About TearLab Corporation

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care.

Get a free copy of the Zacks research report on TearLab Corporation (TEAR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.